Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Repeat expansions confer WRN dependence in microsatellite-unstable cancers
Niek van Wietmarschen, Sriram Sridharan, William J. Nathan, et al.
Nature (2020) Vol. 586, Iss. 7828, pp. 292-298
Open Access | Times Cited: 142

Showing 1-25 of 142 citing articles:

Targeting DNA damage response pathways in cancer
Florian J. Groelly, Matthew Fawkes, Rebecca A. Dagg, et al.
Nature reviews. Cancer (2022) Vol. 23, Iss. 2, pp. 78-94
Closed Access | Times Cited: 468
Hallmarks of DNA replication stress
Sneha Saxena, Lee Zou
Molecular Cell (2022) Vol. 82, Iss. 12, pp. 2298-2314
Open Access | Times Cited: 224
DNA repair defects in cancer and therapeutic opportunities
Jessica L. Hopkins, Li Lan, Lee Zou
Genes & Development (2022) Vol. 36, Iss. 5-6, pp. 278-293
Open Access | Times Cited: 124
Dynamic alternative DNA structures in biology and disease
Guliang Wang, Karen M. Vásquez
Nature Reviews Genetics (2022) Vol. 24, Iss. 4, pp. 211-234
Closed Access | Times Cited: 107
A new wave of innovations within the DNA damage response
Qi Li, Wenyuan Qian, Yang Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 58
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
Stéphane Ferretti, Jacques Hamon, Ruben de Kanter, et al.
Nature (2024) Vol. 629, Iss. 8011, pp. 443-449
Open Access | Times Cited: 35
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
Kristen A. Baltgalvis, Kelsey N. Lamb, Kent T. Symons, et al.
Nature (2024) Vol. 629, Iss. 8011, pp. 435-442
Closed Access | Times Cited: 35
Structure and repair of replication-coupled DNA breaks
Raphael Pavani, Veenu Tripathi, Kyle B. Vrtis, et al.
Science (2024) Vol. 385, Iss. 6710
Closed Access | Times Cited: 31
Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes
Ambrocio Sanchez, Pedro Ortega, Ramin Sakhtemani, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 20
Microsatellite instability: A 2024 update
Hiroyuki Yamamoto, Yoshiyuki Watanabe, Hiroyuki Arai, et al.
Cancer Science (2024) Vol. 115, Iss. 6, pp. 1738-1748
Open Access | Times Cited: 17
Comprehensive interrogation of synthetic lethality in the DNA damage response
John Fielden, Sebastian M. Siegner, Danielle N. Gallagher, et al.
Nature (2025)
Open Access | Times Cited: 2
Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN–driven CCL5 and CXCL10
Courtney Mowat, Shayla R. Mosley, Afshin Namdar, et al.
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 9
Open Access | Times Cited: 87
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
Gabriele Picco, Chiara M. Cattaneo, Esmée J. van Vliet, et al.
Cancer Discovery (2021) Vol. 11, Iss. 8, pp. 1923-1937
Open Access | Times Cited: 74
Advancing genomic technologies and clinical awareness accelerates discovery of disease-associated tandem repeat sequences
Terence Gall-Duncan, Nozomu Sato, Ryan K. C. Yuen, et al.
Genome Research (2021) Vol. 32, Iss. 1, pp. 1-27
Open Access | Times Cited: 64
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
Wantao Wu, Yihan Liu, Shan Zeng, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 57
Resistance to DNA repair inhibitors in cancer
Joseph S. Baxter, Diana Zatreanu, Stephen J. Pettitt, et al.
Molecular Oncology (2022) Vol. 16, Iss. 21, pp. 3811-3827
Open Access | Times Cited: 53
Recurrent repeat expansions in human cancer genomes
Graham S. Erwin, Gamze Gürsoy, Rashid Al-Abri, et al.
Nature (2022) Vol. 613, Iss. 7942, pp. 96-102
Open Access | Times Cited: 50
S1-END-seq reveals DNA secondary structures in human cells
Gabriel Matos‐Rodrigues, Niek van Wietmarschen, Wei Wu, et al.
Molecular Cell (2022) Vol. 82, Iss. 19, pp. 3538-3552.e5
Open Access | Times Cited: 42
Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats
Julia Su Zhou Li, Ammal Abbasi, Dong Hyun Kim, et al.
Nature (2023) Vol. 616, Iss. 7957, pp. 504-509
Open Access | Times Cited: 41
Detection of alternative DNA structures and its implications for human disease
Gabriel Matos‐Rodrigues, Julia A. Hisey, André Nussenzweig, et al.
Molecular Cell (2023) Vol. 83, Iss. 20, pp. 3622-3641
Open Access | Times Cited: 37
Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
Gabriele Picco, Yanhua Rao, Angham Al Saedi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 8, pp. 1457-1475
Closed Access | Times Cited: 17
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
Yvette Drew, Frank T. Zenke, Nicola J. Curtin
Nature Reviews Drug Discovery (2024) Vol. 24, Iss. 1, pp. 19-39
Closed Access | Times Cited: 16
The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance
Justin L. Engel, Xiao Zhang, Mingming Wu, et al.
Cell (2024) Vol. 187, Iss. 21, pp. 6055-6070.e22
Closed Access | Times Cited: 11
Challenges for the Discovery of Non‐Covalent WRN Helicase Inhibitors
Alisa Heuser, Wassim Abdul Rahman, Elisabeth Bechter, et al.
ChemMedChem (2024) Vol. 19, Iss. 8
Closed Access | Times Cited: 10
The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy
Meiyi Ge, Jian Luo, Yi Wu, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top